-transparent.png){kind=logo}
For eight weeks 30 psychotic patients with a healthy cardiovascular system received 3 X 50 mg 1-[3-(10,11-dihydro=5H-dibenz[b,f]-azepin-5-yl]-propyl]-4-piperidiono-piperdine-4-carboxamide dihydrochloride-monohydrate (carpipramine) per day with a placebo phase of three weeks either previous to the medication of succeeding it. In addition there was a group of similar patients without any medication. From this study it was concluded that carpipramide has no depressive effect on the cardiovascular system. The differences in blood pressure and heart rate after the change from medication to placebo indicate a certain vegetative lability in this phase. In the ECG, no irregularities of the atrioventricular and intraventricular conduction and its repolarisation in form of a lengthening were observed; only the WPW-syndrome noticed with one patient might be related to the medication since it occurred at the end of the three weeks during which carpipramine had been administered.
F Eckmann, and
J Sommer, and
W Trummer
January 1976,
Arzneimittel-Forschung,
F Eckmann, and
J Sommer, and
W Trummer
October 1978,
Praktische Anasthesie, Wiederbelebung und Intensivtherapie,
F Eckmann, and
J Sommer, and
W Trummer
March 1977,
Therapeutische Umschau. Revue therapeutique,
F Eckmann, and
J Sommer, and
W Trummer
September 1981,
Zeitschrift fur Kardiologie,
F Eckmann, and
J Sommer, and
W Trummer
December 1977,
Medizinische Klinik,
F Eckmann, and
J Sommer, and
W Trummer
January 1978,
Chirurgie; memoires de l'Academie de chirurgie,
F Eckmann, and
J Sommer, and
W Trummer
October 1977,
Leber, Magen, Darm,
F Eckmann, and
J Sommer, and
W Trummer
September 1980,
Revue medicale de Bruxelles,
F Eckmann, and
J Sommer, and
W Trummer
August 1975,
Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
F Eckmann, and
J Sommer, and
W Trummer
August 1974,
Der Anaesthesist,
